March 2018

A research contract was signed between Ikonisys and the Trentino, Italy industrial district.

March 2018

A collaboration agreement was signed between Ikonisys, Impact Labs, Milan, Italy and Prof. Bruno Vincenzi, Oncology Department, University Campus Bio-Medico, Rome, Italy. The agreement will facilitate the application of Ikonisys’ rare-cell analysis technology to the detection of circulating tumor cells (CTCs) in sarcoma. Detection of CTCs has been proposed to have clinical significance as a prognostic or predictive marker in sarcoma and, as a measure of metastatic potential, could provide a way to target a patient population more likely to benefit from adjuvant chemotherapy.

February 2018

Ikonisys has initiated a collaboration with Prof. Dr. Olga Golubnitschaja of the European Association for Predictive, Preventive & Personalised Medicine. The main concept of the collaborative project, which will involve partners in both the USA and Europe, is to create an innovative breast cancer predictive and diagnostic approach particularly useful for young women whose needs are not covered by currently existing screening programmes. The intention is to combine the elements of established expertise for the proof of principle model of new medical services to be offered to the populations. The project will highlight the potential clinical utility of the Ikonisys CTC detection technology in this patient population.

November 2017

Ikonisys has joined the European Association for Predictive, Preventive & Personalised Medicine as an Institutional Member. The EPMA was founded in 2009 to cover particular deficits in medical sciences and healthcare. The main objective of the EPMA is to promote the paradigm change from delayed reactive medical services to evidence-based Predictive, Preventive & Personalised Medicine (PPPM) as an integrated science and healthcare practice. As an Institutional Member, Ikonisys will have the opportunity to contribute to this rapidly emerging field by virtue of the company’s rare cell analysis platform.

September 2017

Ikonisys presented “Detection and Analysis of Circulating Tumour Cells in Small Cell Lung Cancer Utilizing a Flexible Rare Cell Scanning Platform” at the EPMA World Congress 2017 'Predictive, Preventive & Personalised Medicine'. The presentation outlined the application of the Ikonisys platform to detection and analysis of circulating tumour cells. The Abstract of the presentation was published in the EPMA journal (Kilpatrick MW, Kershnar ER, Borgerding RH, Robson P, Sivakamasundari V. EPMA J 2017; 8 (Suppl 1):S9-S10).

June 2017

The result of a collaboration between Ikonisys and Dr. Upendra Hegde, UConn Health, Connecticut, USA, was presented at the annual meeting of the American Society of Clinical Oncology (Determination of the potential of detecting 3q gain as a valuable biomarker in the management of patients with HPV associated oropharyngeal squamous cell carcinoma). The work demonstrated the ability of the Ikonisys platform to detect gain of the chromosomal 3q locus in cytological brushings from patients undergoing treatment for oropharyngeal squamous cell carcinoma, with the potential to have clinical utility in the management of such patients.